BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Sales'. (Return)

Yahoo BusinessOct 28, 2020
Ford Posts Strong Third-Quarter Earnings, Sees 2020 Profit
(Bloomberg) -- Ford Motor Co., riding a wave of momentum from new models and new management, handily beat expectations with third-quarter earnings that outran the economic effects of the coronavirus pandemic.Fueled by strong sales of pricey pickups, Ford posted adjusted earnings per share of 65 cents, well above the 19 cents analyst consensus forecast. Big profits in North America offset weakness overseas, allowing the company to revise its full-year forecast. It now expects to stay in the black this year, a reversal from an earlier outlook for its first annual loss in a decade.Ford's stock rose as much as 7.8% in postmarket trading after closing Wednesday at $7.70. The shares are down about 17% this year.The long-suffering automaker is enjoying a surge in sentiment since industry veteran Jim Farley became chief executive officer Oct. 1, replacing retiring Jim Hackett, to whom Wall Street never warmed. Intense and demanding, Farley is expected to jumpstart a turnaround that has been sputtering for years. The latest quarterly results help position the company to put the worst behind it.Ford said adjusted earnings before interest and taxes came to $3.6 billion in the quarter compared with $1.8 billion a year ago. Revenue in the quarter was $37.5 billion, above the $33.98 billion analysts anticipated.Unresolved IssuesFarley said the bullish performance belies underlying woes that need to be resolved before the carmaker can achieve its goal of sustainable profit margins above 10% in its core North American market."

CNBC BusinessOct 28, 2020
Gilead's revenue rises 17% driven by sales of coronavirus treatment remdesivir
Remdesivir generated $873 million in sales during the third quarter, mostly in the U.S., the company said.

RELATED ARTICLES
Gilead Sales Up 18% in Q3, Thanks to Coronavirus Treatment Remdesivir (The Motley Fool)

MarketWatchOct 28, 2020
Earnings Results: Fast start for coronavirus drug boosts Gilead earnings, but stock sinks on forecast
In the first quarter of sales of its COVID-19 antiviral drug, Gilead Sciences Inc. produced better profit and sales than expected, buts its beleaguered shares were hit by a reduction in its annual sales forecast Wednesday.

Yahoo BusinessOct 28, 2020
NCR's 3Q Sales Dive 11% As Covid-19 Hurts Hardware Business
NCR Corp.'s 3Q revenues fell 11% to $1.59 billion year-over-year dragged down by a 26% decline in hardware sales. However, revenues of the ATM (automated teller machine) and POS (Point-Of-Sale) hardware and software solution provider came ahead of analysts' estimates of $1.55 billion.NCR's (NCR) ATM hardware sales plunged 40% as the COVID-19 pandemic impacted ATM installation activities. Moreover, its SCO/POS (Self-Checkout/Point-Of-Sale) hardware sales shrank 6% on a year-on-year basis.The company's 3Q adjusted EPS decreased by 26% to $0.54 year-on-year but came ahead of the Street estimates of $0.36.NCR's CEO Michael Hayford said, "Our third quarter performance reflects solid execution of our strategy and the resiliency of our solutions in a difficult operating environment that continues to be impacted by COVID-19." He further noted, "Looking ahead, we still face a challenging operating environment but we remain confident in our ability to execute our strategy and grow recurring revenue, drive cash flow generation and expand margins." (See NCR stock analysis on TipRanks).Ahead of its earnings release, J.P. Morgan analyst Paul J Chung upgraded the stock to Buy from Hold and raised the price target to $27 (23% upside potential) from $21. Chung is encouraged by NCR's margin structure and free cash flow outlook. The analyst sees modest growth in ATMs per branch and forecasts a steady fundamental recovery over the next 6-12 months.Currently, the Street is bullish on the stock. The Strong Buy analyst consensus is based on

Wall Street Journal US BusinessOct 28, 2020
Gilead Quarterly Revenue Rises on Remdesivir Sales
Gilead Sciences' revenue rose 17%, helped by sales of its antiviral drug Remdesivir that has become a standard treatment for hospitalized Covid-19 patients.

RELATED ARTICLES
: Sturm Ruger stock rises as unrest drives sales (MarketWatch MarketPulse)

Wall Street Journal US BusinessOct 27, 2020
Caterpillar, 3M Flag Falling Sales to Businesses
Results from industrial giants Caterpillar and 3M show demand from commercial customers is on shaky ground as the Covid-19 pandemic continues to disrupt work routines and commerce.
TRENDING TAGS
EarningsCall Transcript Q3 Inc stock
StockEarnings market Dow Today Covid
Covid-19cases Stocks Surge Points Global
PointsDow Cases Stocks futures rise
casesCoronavirus Points Dow Covid Covid-19
StocksDow COVID-19 Points Covid Surge
PandemicDuring Boeing Earnings jobs Business
Coronaviruscases latest record Dow points
DowPoints Down cases stocks Coronavirus
COVIDCovid-19 cases Stocks Surge global

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC